INTRODUCTION AND OBJECTIVES: Early detection of bladder cancer metastases might provide the potential for early treatment of metastatic disease. We previously reported on the use of a bladder tumor-binding peptide (BTBP)2 coupled to a Gd-DOTA MRI contrast agent (BTBP-probe)3 delivered intravesically to visualize bladder cancer growing on the bladder surface of an orthotopic mouse model, In this new report we demonstrated the use of this probe delivered intravenously to detect micrometastic spread of cancer to distant organs. METHODS: MRI Studies: MRI experiments were done on a Bruker Biospec 7.0 Tesla/30 cm horizontal-bore imaging system. Multiple abdominal region 1H-MR image slices were taken using a RARE multislice (repetition time (TR) 1.3 s, echo time (TE) 9 ms, 256x256 matrix, 4 steps per acquisition, 3x3 cm2 field of view, 0.75 mm slice thickness). Mouse abdominal organs were imaged at 0 (pre-contrast) and at 3-4 hours post-contrast agent injection. Mice were injected intravenously with the BTBP-Gd-DOTA contrast agent (100ml/mouse; 50mmol/L). T1-weighted images were obtained using a variable TR (repetition time) spin-echo sequence (TR, 200-1600 ms; TE, 15 ms; NA, 2) . Pixel-by-pixel relaxation maps were reconstructed from a series of T1-weighted images using a nonlinear two-parameter fitting procedure. The T1 value of a specified region-of-interest (ROI) was computed from all the pixels in the identified ROIs. MRI scans were obtained 6-7 weeks post-implantation of bladder tumors to identiy metastatic lesions.
RESULTS: Molecular MRI (mMRI) was used to detect the presence of the BTBP-probe via a substantial decrease in T1 relaxation, measured as T1 relaxation difference, within tumor regions of mice administered the BTBP-probe (p<0.05) compared to the controls. Both primary and metastatic tumors were detected.
CONCLUSIONS: We used mMRI to show for the first time noninvasive in vivo early detection of bladder tumor metastases in a mouse model for bladder carcinoma. Using mMRI with a bladder tumor-binding peptide targeted probe provides the advantage of in vivo image resolution and spatial differentiation of regional events in early detection of bladder cancer metastases.
Source of Funding: Funds from Stephenson Cancer Center

PNFLBA-15
Alan Partin*, Baltimore, MD; Phillipp Torkler, Mikkel Noerholm, Martinsried, Germany; Johan Skog, Cambridge, MA; Michael Donovan, NYC, NY INTRODUCTION AND OBJECTIVES: Overdetection and overtreatment of indolent prostate cancer (PCa) remains a significant health issue requiring noninvasive assays to guide the prostate biopsy decision process. We previously demonstrated that a non-DRE urine exosome gene expression assay (ExoDx Prostate (IntelliScore) (EPI) discriminates GS 7 PCa from GS 6 and benign disease, potentially reducing the number of unnecessary biopsies. We initiated a novel prospective, phase-adaptive two cohort trial design: Group 1 (G1), men scheduled for a biopsy and Group 2 (G2), men for which the decision to biopsy is uncertain. The G1 consensus results including EPI cut-point recommendation will be applied to G2 patients with clinical utility, ease of adoption, patient response and health economic data collected. Here we report interim results from G1 with initial cut-point comparison to the original validation trial.
METHODS: The trial was activated on Sept. 2016 at 9 sites (8 community practice, 1 academic), geographically distributed across the U.S. We plan to enlist up to 20 sites by April 2017. Enrollment is limited to initial biopsy patients only, >/¼50 years with PSA 2-10 ng/mL. The EPI test is performed at Exosome Diagnostics' CLIA laboratory in Cambridge, MA; G1 results are collected for consensus review and G2 recommendation.
RESULTS: The average biopsy rate across all sites is 1-2 / week. Demographics of the 96 (of targeted) 500 G1 patients enrolled thus far are comparable to the validation study (mean age 64 years, mean PSA 5.78; 75% white, 17% African American, 23% positive family history of PCa, 81% non-suspicious DRE). Of note, we have observed a higher positive biopsy rate of 59% (vs. 47% in validation study); 22% ISUP 1 (GS 3+3) and 37% >/¼ISUP 2. The EPI test validated (15.6) vs.
adjusted (20) cut-points both result in NPV 90, with sensitivity of 94% and 92%, respectively. The number of avoided biopsies is greater (30%) with the adjusted cut-point of 20 vs. the original validated cutpoint (21%); while missing only 1>/¼ISUP 3 case. The original validated cut-point would have avoided biopsies in 30% of men with GS6 or benign disease while the adjusted cut-point would have avoided 43% of biopsies in this population.
CONCLUSIONS: Interim results from a prospective adaptive trial of the EPI test demonstrate consistent performance as identified in the original validation study. The adjusted cut-point continues to provide added benefit without risk of missing significant disease.
Source of Funding: Private
PNFLBA-16 FIRST RESULTS OF A-PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY
INTRODUCTION AND OBJECTIVES:
Axitinib is a potent oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) not previously tested in the UK in metastatic RCC patients with their primary tumour in situ. A-PREDICT aims to determine whether axitinib has activity in this population and explore biomarkers of activity and resistance METHODS: A-PREDICT is a phase II single group study (maximum n¼99) of axitinib (starting dose 5mg BID) in patients with metastatic clear cell RCC unable to have immediate cytoreductive nephrectomy. Participants consented to provide biosamples (tumour, blood, urine) at baseline, on treatment and at progression. The primary endpoint is proportion of patients alive and free from disease progression (RECIST v1.1) at 6 months. Secondary endpoints include toxicity (CTCAE v4), progression free, overall survival and correlation of biomarkers with clinical endpoints.
RESULTS: 65 participants were recruited between 10/10/2012 and 23/12/2016. In December 2016 the Independent Data Monitoring and Steering Committee recommended that the trial close to recruitment as the pre-defined threshold level of activity had been reached. As of 19/12/2016 tumour samples were available for 92% participants at baseline, 87% on treatment and 13% at progression with equivalent return rates for blood and for urine samples. Final data on response and toxicity will be available Q2 2017. CONCLUSIONS: Recruitment to translational studies is challenging. Due to close cooperation of oncologists, urologists, radiologists and pathologists, A-PREDICT represents the largest UK translational therapeutic study of first line treatment using axitinib in metastatic RCC, presenting a unique opportunity to study mechanisms of sensitivity and resistance to axitinib. Importantly, axitinib met predefined activity thresholds.
Source of Funding: Pfizer
PNFLBA-17 DETECTION OF CIRCULATING TUMOR CELL IN THE PATIENTS WITH PROSTATE CANCER USING NOVEL VIRAL MARKER OBP-1101
Nobuyuki Hinata*, Yukari Bando, Akira Miyazaki, Tomoaki Terakawa, Junya Furukawa, Kenichi Harada, Masato Fujisawa, Kobe, Japan INTRODUCTION AND OBJECTIVES: Circulating tumor cell (CTC) is reported in several studies as a promising predictor of survival or treatment response. However, CTC detection by using immunohistochemical techniques some limitations, such as dead cancer cells could be detected, insufficient sensitivity, or inability to detect epithelialmesenchymal transformation (EMT). OBP-1101 is a novel adenovirusderived detection marker for cancer cells. Green Fluorescent Protein (GFP) protein gene expression is controlled by telomerase promoter in OBP-1101 and might be resolve above-mentioned problems.
METHODS: After IRB approval, 15 ml blood samples were collected from 49 patients with prostate cancer at Kobe University Hospital. Detection of CTC using OBP-1011 was performed and these results were compared with patient demographics. Clinical stage, Gleason score, PSA, NCCN risk classification were analyzed whether they correlate with GFP positivities. In addition, results of immunohistochemical staining using EpCAM antibody and PSMA antibody were compared with GFP positivities.
RESULTS: GFP positive CTC was detected in 26 cases (53.1%). EpCAM positive CTC was detected in 28 cases (57.1%). Among 28 EpCAM positive cases, PSMA positive CTCs were detected in 25 cases (89.3%). On the other hand, PSMA positive CTCs were detected only in 4 cases (8.2%). None of the Clinical stage, Gleason score, PSA, risk classification correlated with GFP positivity or EpCAM positivity.
CONCLUSIONS: The CTCs detected by using OBP-1101 could have different characteristics from those detected by using epithelial markers. These characteristics to detect EMT might be markers of worse clinical outcomes and change clinical decision making.
